NexMed Confirms FDA Acceptance Of NDA For Erectle Dysfunction Product
NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, announced that the New Drug Application (NDA) filed by the Company for its erectile dysfunction (ED) product, a topically applied alprostadil cream, was accepted for review by the U.S. Food and Drug Administration (FDA). [click link for full article]
More: continued here
Filed under: Erectile Dysfunction / Premature Ejaculation on December 2nd, 2007